Duration by Design: Discovery of Revefenacin, the First-in-Class Nebulized Once-Daily Bronchodilator for the Treatment of Patients With COPD-Reference-Cited by-同舟云学术

Duration by Design: Discovery of Revefenacin, the First-in-Class Nebulized Once-Daily Bronchodilator for the Treatment of Patients With COPD

Published:2016-10 Issue:4 Volume:150 Page:970A
ISSN:0012-3692
Container-title:Chest
language:en
Short-container-title:Chest

Author:

Ji Yuhua,Husfeld Craig,Pulido-Rios M. Teresa,McNamara Alexander,Obedencio Glenmar P.,Baldwin Mike,Bourdet David,Hegde Sharath,Mammen Mathai,Moran Edmund

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine,Critical Care and Intensive Care Medicine,Pulmonary and Respiratory Medicine

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of Isaria cicadae on growth, gut microbiota, and metabolome of Larimichthys crocea;Fish & Shellfish Immunology;2023-05

2. Revefenacin, a once-daily, long-acting muscarinic antagonist, for nebulized maintenance therapy in patients with chronic obstructive pulmonary disease;American Journal of Health-System Pharmacy;2021-04-04

3. Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysis;BMC Pulmonary Medicine;2020-05-11

4. Efficacy and safety of revefenacin for nebulization in patients with chronic obstructive pulmonary disease taking concomitant ICS/LABA or LABA: subgroup analysis from phase III trials;Therapeutic Advances in Respiratory Disease;2020-01

Revefenacin: A Once-Daily, Long-Acting Bronchodilator For Nebulized Treatment Of COPD

;International Journal of Chronic Obstructive Pulmonary Disease;2019-12